Further, dual targeting of CCR2+ TAMs and CXCR2+ TANs restored anti‐tumour immunity and improved the chemotherapeutic effect, providing the theoretical basis for targeting both CCR2 and CXCR2 in future clinical trials.157. Here, CCR2 is linked to neoplasm.